Novo’s Rybelsus Pill Set To Disrupt Europe’s Diabetes Market
Executive Summary
Rybelsus, the first oral GLP-1 treatment for type 2 diabetes, will likely secure EU approval in a couple of months.
You may also be interested in...
Novo Nordisk Pays $1.80bn To Buy Emisphere
The Danish major will develop the US firm's technology and use it on current and future pipeline assets with the aim of making more biologics orally available.
EU Firsts Beckon For Alnylam & Novo; Wins For A Raft Of Others
A plethora of new drugs moved closer to the EU market this week after the European Medicines Agency recommended that they should be approved.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.